BCDA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 20.00%

Insider Buying (Last 12 Months): $76,626.05

Insider Selling (Last 12 Months): $6,514.00

BioCardia Insider Trading History Chart

BioCardia Share Price & Price History

^$2.01

▲ +0.025 (1.26%)

As of 04/8/2025 04:59 PM ET

Days: 30 | 90 | 365

BioCardia Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/7/2025	Peter Altman	CEO	Buy	500	$1.96	$980.00	112,020
4/3/2025	Peter Altman	CEO	Buy	1,200	$2.24	$2,688.00	109,620
3/5/2025	Simon H Stertzer	Director	Buy	1,000	$2.45	$2,450.00	57,138
3/3/2025	Peter Altman	CEO	Buy	500	$2.11	$1,055.00	108,420
3/3/2025	Simon H Stertzer	Director	Buy	22,753	$2.30	$52,331.90	40,602
2/7/2025	Peter Altman	CEO	Buy	600	$2.48	$1,488.00	107,920
1/29/2025	Peter Altman	CEO	Buy	500	$2.40	$1,200.00	107,081
12/23/2024	Peter Altman	CEO	Buy	1,000	$2.06	$2,060.00	106,581
12/20/2024	Edward M Gillis	SVP	Sell	3,257	$2.00	$6,514.00	8,968
12/5/2024	Peter Altman	CEO	Buy	250	$2.22	$555.00	105,581
11/15/2024	Peter Altman	CEO	Buy	1,350	$1.87	$2,524.50	105,331
7/1/2024	Peter Altman	CEO	Buy	300	$3.05	$915.00	39,745
6/28/2024	Peter Altman	CEO	Buy	200	$2.99	$598.00	39,445
6/21/2024	Peter Altman	CEO	Buy	500	$3.29	$1,645.00	39,245
6/14/2024	Peter Altman	CEO	Buy	500	$3.52	$1,760.00	38,745
6/10/2024	Peter Altman	CEO	Buy	1,000	$3.36	$3,360.00	38,245
4/19/2024	Peter Altman	CEO	Buy	183	$5.55	$1,015.65	37,246
3/28/2024	Peter Altman	CEO	Buy	33	$5.85	$193.05	37,063
2/13/2024	Peter Altman	CEO	Buy	7,207	$6.90	$49,728.30	37,029
1/19/2024	Phillip Md Et Al Frost	Major Shareholder	Sell	8,653	$6.45	$55,811.85	126,401
5/26/2023	Peter Altman	CEO	Buy	413	$24.00	$9,912.00	31,282
1/11/2023	Peter Altman	CEO	Buy	6	$28.05	$168.30	23,581
12/16/2022	Phillip Md Et Al Frost	Major Shareholder	Buy	39,682	$25.20	$999,986.40	135,055
10/10/2022	David Mcclung	CFO	Buy	133	$31.05	$4,129.65	5,234
9/23/2022	Peter Altman	CEO	Buy	93	$28.05	$2,608.65	21,896
9/21/2022	Peter Altman	CEO	Buy	183	$28.80	$5,270.40	21,596
6/10/2022	Peter Altman	CEO	Buy	300	$21.90	$6,570.00	21,413
5/13/2022	Peter Altman	CEO	Buy	179	$20.70	$3,705.30	23,209
5/11/2022	Peter Altman	CEO	Buy	66	$19.50	$1,287.00	22,276
4/28/2022	Peter Altman	CEO	Buy	153	$23.85	$3,649.05	22,029
4/18/2022	Peter Altman	CEO	Buy	900	$20.85	$18,765.00	21,876

See Full Table

SEC Filings (Institutional Ownership Changes) for BioCardia (NASDAQ:BCDA)

20.57% of BioCardia stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

BioCardia Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/12/2025	Geode Capital Management LLC	30,987	$68K	0.0%	+110.3%	0.677%
2/7/2025	CM Management LLC	25,000	$54K	0.0%	N/A	0.546%
11/7/2023	CM Management LLC	600,000	$0.26M	0.3%	+74.9%	2.775%
8/4/2023	CM Management LLC	343,000	$0.92M	0.9%	+4.3%	1.677%
7/24/2023	Vontobel Holding Ltd.	30,751	$82K	0.0%	+93.5%	0.150%
5/15/2023	AIGH Capital Management LLC	509,151	$0.99M	0.4%	-14.5%	2.523%
4/12/2023	Vontobel Holding Ltd.	15,895	$31K	0.0%	N/A	0.079%
2/16/2023	AIGH Capital Management LLC	595,237	$1.24M	0.4%	N/A	2.969%
11/15/2022	Family Management Corp	142,186	$0.28M	0.1%	N/A	0.797%
5/4/2022	Commonwealth Equity Services LLC	49,978	$0.10M	0.0%	+18.1%	0.296%
1/31/2022	Commonwealth Equity Services LLC	42,307	$82K	0.0%	+156.5%	0.251%
11/5/2021	Advisor Group Holdings Inc.	39,257	$0.12M	0.0%	-8.4%	0.233%
10/29/2021	Commonwealth Equity Services LLC	16,492	$51K	0.0%	N/A	0.098%
9/17/2021	Virtu Financial LLC	33,264	$0.13M	0.0%	N/A	0.197%
8/25/2021	Marshall Wace LLP	21,680	$86K	0.0%	-45.7%	0.129%
8/16/2021	Marshall Wace LLP	21,680	$86K	0.0%	-45.7%	0.129%
8/13/2021	Renaissance Technologies LLC	102,230	$0.41M	0.0%	-66.5%	0.609%
8/13/2021	Geode Capital Management LLC	76,825	$0.30M	0.0%	+23.6%	0.457%
8/13/2021	Vanguard Group Inc.	411,969	$1.64M	0.0%	+67.8%	2.453%
8/10/2021	CM Management LLC	329,000	$1.31M	0.9%	+5.1%	1.959%
8/6/2021	Magnus Financial Group LLC	15,000	$60K	0.0%	N/A	0.089%
5/19/2021	Squarepoint Ops LLC	46,945	$0.20M	0.0%	N/A	0.280%
5/13/2021	Renaissance Technologies LLC	305,200	$1.33M	0.0%	N/A	1.817%
5/12/2021	Geode Capital Management LLC	62,168	$0.27M	0.0%	+175.6%	0.370%
5/12/2021	CM Management LLC	313,100	$1.36M	1.0%	+36.1%	1.864%
2/9/2021	Bank of New York Mellon Corp	16,294	$56K	0.0%	N/A	0.131%

Data available starting January 2016

See Full Table

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Today's Range

Now: $2.01

$1.94

$2.01

50 Day Range

MA: $2.45

$1.99

$2.84

52 Week Range

Now: $2.01

$1.63

$6.15

Volume

20,634 shs

Average Volume

279,031 shs

Market Capitalization

$9.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.21

Who are the company insiders with the largest holdings of BioCardia?: BioCardia's top insider investors include:
Phillip Md Et Al Frost (Major Shareholder)
Peter Altman (CEO)
Simon H Stertzer (Director)
Edward M Gillis (SVP)
Learn More about top insider investors at BioCardia.